Lupin Q3 FY26 consolidated PAT jumped 37.4% to Rs. 1,180.5 Cr

U.S. market achieved record quarterly sales of Rs. 3,113.2 crore ($350 million), a 54% YoY increase, accounting for 44% of global sales

Aurobindo Pharma reports strong Q3 FY26 performance, boosted by Europe & ARV growth

Syngene collaborates with Johns Hopkins University to advance early-stage drug discovery

The collaboration is anchored in Syngene’s SynVent platform and Connector model to accelerate promising academic research

Motorica showcases advanced prosthetics expertise at OPAI National Conference

Motorica India conducted a specialised masterclass led by Shumaev, centred on real-life rehabilitation scenarios and personalised therapy programs before and after prosthetic fitting

Roche BTK drug emerges as potential breakthrough in primary progressive MS

Zydus Lifesciences reports strong Q3 & 9M FY26 growth

Revenue from operations surged 30% year-on-year to Rs. 68,645 million

GSK India crosses Rs. 1,000 crore mark, key portfolios drive 8.1% topline growth

Launched in August 2025, GSK India’s Oncology business is rapidly gaining momentum

Neuland Laboratories reports Rs 1,264.5 crore revenue for 9MFY26

The revenues this quarter are in line with the outlook we envisaged for the year

SMS Pharmaceuticals posts strong Q3 with 29% PAT growth, full-year targets on track

The company’s EBITDA margin remained resilient above 20%

Biomica seals exclusive global license for groundbreaking microbiome cancer therapy

The therapy is currently completing Phase 1 clinical trials in renal cell carcinoma and non-small cell lung cancer